<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H5BACED6367A54BA8A85C8A62E55CFC94" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1020 IH: Compassionate Freedom of Choice Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-02-13</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1020</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170213">February 13, 2017</action-date><action-desc><sponsor name-id="G000568">Mr. Griffith</sponsor> (for himself and <cosponsor name-id="B001290">Mr. Brat</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To allow the manufacture, importation, distribution, and sale of investigational drugs and devices
			 intended for use by terminally ill patients who execute an informed
			 consent document, and for other purposes.</official-title></form>
	<legis-body id="H3E8E411A3E60447681E16F64DB39FCD2" style="OLC">
 <section id="HF7F46EE6F95B4BFEBC3B84A254F3A3A3" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Compassionate Freedom of Choice Act of 2017</short-title></quote>.</text> </section><section id="H241BDFBE100D4A628519A4CE9967212C"><enum>2.</enum><header>Drugs and devices for use by terminally ill patients</header><text display-inline="no-display-inline">The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 561 (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb</external-xref>) the following:</text>
			<quoted-block display-inline="no-display-inline" id="H1FBCC3E41D1A4AFB8A81BBFD3B557F48" style="OLC">
				<section id="HE8BF9B31E83247BC8C7B82266F33AA68"><enum>561A.</enum><header>Drugs and devices for use by terminally ill patients</header>
 <subsection id="H555F02E3121B4FDCAE0B66FAD8457789"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Nothing in this Act or section 351 of the Public Health Service Act prevents or restricts, and the Food and Drug Administration shall not implement or enforce any provision of law preventing or restricting, the manufacture, importation, distribution, or sale of an investigational drug or device intended for use by a terminally ill patient in accordance with subsection (b).</text>
 </subsection><subsection id="H61440644BB1A4855959A04F74B1535EA"><enum>(b)</enum><header>Patient requirements</header><text display-inline="yes-display-inline">In order for an investigational drug or device to be intended for use in accordance with this subsection, such drug or device must be intended for use by a patient who has—</text>
 <paragraph id="HF3E9CA8704344D0D904489C6BE2D60B4"><enum>(1)</enum><text display-inline="yes-display-inline">been diagnosed with a terminal illness by a licensed physician;</text> </paragraph><paragraph id="HC6F3F05A16764DB4A75CA9C2D8EBEA2A"><enum>(2)</enum><text display-inline="yes-display-inline">been informed by a licensed physician that no drug or device that is lawfully marketed in the United States is likely to cure the illness; and</text>
 </paragraph><paragraph id="H1CF267B5CF4843FA939748DE6B065DA4"><enum>(3)</enum><text>executed a written informed consent document that states—</text> <subparagraph id="H0D97654B58BB4AFC9D613C6062E32E7D"><enum>(A)</enum><text>the known and potential risks and benefits of such drug or device; and</text>
 </subparagraph><subparagraph id="H20F61B14691941E192A5A3F4422C6663"><enum>(B)</enum><text display-inline="yes-display-inline">any indications of the illness for which a drug or device is lawfully marketed, or for which treatment is otherwise available, in the United States.</text>
							</subparagraph></paragraph></subsection><subsection id="H2332A0BF8C2B435DA11EFEBB06856432"><enum>(c)</enum><header>Prohibition on requiring the disclosure, collection, and reporting of certain information by Food
			 and Drug Administration</header>
 <paragraph id="H5AE8804E94B340B3932E4042E65DFF0A"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Commissioner of Food and Drugs may not require the disclosure, collection, or reporting of—</text> <subparagraph id="H6AFAB958A49E41C181392726BB167E5F"><enum>(A)</enum><text>any information related to the delivery, administration, or use of an investigational drug or device pursuant to this section; or</text>
 </subparagraph><subparagraph id="HE41221E2AFFC4A70B6B4227C4BAF112C"><enum>(B)</enum><text>any information related to the clinical outcomes experienced by a terminally ill patient supplied an investigational drug or device pursuant to this section.</text>
 </subparagraph></paragraph><paragraph id="H26DC03A5611F40D7B694BBF55FC35106"><enum>(2)</enum><header>Exception</header><text display-inline="yes-display-inline">Nothing in this subsection prevents the sponsor of a clinical trial from voluntarily disclosing, collecting, or reporting information to the Food and Drug Administration.</text>
 </paragraph></subsection><subsection id="HAE39DBC0AC91432083F6FDC5E27239F5"><enum>(d)</enum><header>Definition of investigational drug or device</header><text display-inline="yes-display-inline">In this section, the term <term>investigational drug or device</term> means a drug or device that—</text> <paragraph id="HFA47DF2683854D31A0D3741B5B398A0C"><enum>(1)</enum><text display-inline="yes-display-inline">has not yet been approved, licensed, or cleared for commercial distribution under section 505, 510(k), or 515 of this Act or section 351 of the Public Health Service Act, and cannot otherwise be lawfully marketed in the United States; and</text>
 </paragraph><paragraph id="H5D2E17BC56034035862941AA74B952A3"><enum>(2)</enum><text>is or has been the subject of one or more clinical trials.</text></paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </section><section commented="no" id="HD9356C6D1107446A92FC77A7A830A634"><enum>3.</enum><header>Liability protection</header><text display-inline="no-display-inline">The Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301</external-xref> et seq.) is amended by inserting after section 561A, as inserted by section 2 of this Act, the following:</text>
			<quoted-block id="H6A56E4931FD24597920E7BAD4505B697">
 <section commented="no" id="HC6793EA8DAA24B6C9855019F796540F5"><enum>561B.</enum><header>Liability protection</header><text display-inline="no-display-inline">Except in the case of gross negligence or willful misconduct, any person who manufactures, imports, distributes, prescribes, dispenses, or administers an investigational drug or device in accordance with section 561A shall not be liable in any action under Federal or State law for any loss, damage, or injury arising out of, relating to, or resulting from—</text>
 <paragraph commented="no" id="H20EF2CF644794AC7AA24AA6414AD37CE"><enum>(1)</enum><text>the design, development, clinical testing and investigation, manufacturing, labeling, distribution, sale, purchase, donation, dispensing, prescription, administration, or use of the drug or device; or</text>
 </paragraph><paragraph commented="no" id="H19B3D44CF55F407F84968A847EE952BC"><enum>(2)</enum><text>the safety or effectiveness of the drug or device.</text></paragraph></section><after-quoted-block>.</after-quoted-block></quoted-block> </section></legis-body></bill> 

